Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Candidate malaria vaccines have failed to elicit consistently protective immune responses against challenge with Plasmodium falciparum. NYVAC-Pf7, a highly attenuated vaccinia virus with 7 P. falciparum genes inserted into its genome, was tested in a phase I/IIa safety, immunogenicity, and efficacy...

Full description

Bibliographic Details
Main Authors: Ockenhouse, C, Sun, P, Lanar, D, Wellde, B, Hall, B, Kester, K, Stoute, J, Magill, A, Krzych, U, Farley, L, Wirtz, R, Sadoff, J, Kaslow, D, Kumar, S, Church, L, Crutcher, J, Wizel, B, Hoffman, S, Lalvani, A, Hill, A, Tine, J, Guito, K, de Taisne, C, Anders, R, Ballou, W
Format: Journal article
Language:English
Published: 1998

Similar Items